Lenvima (lenvatinib capsules) — Cigna

Endometrial Carcinoma

Initial criteria

Patient age ≥ 18 years
Patient meets ONE of the following (i or ii):
i. Patient meets ALL of the following (a, b, and c):
a) Patient has advanced endometrial carcinoma that is mismatch repair proficient (pMMR)
b) The medication is used in combination with Keytruda (pembrolizumab intravenous injection)
c) Patient has tried at least one systemic therapy
ii. Lenvima is used as a single agent for second-line or subsequent therapy
Patient is not a candidate for curative surgery or radiation

1 year